DOI: 10.36347/sjmcr.2022.v10i02.020

Pages: 125-130

Gliosarcoma (GSM) is a rare central nervous system malignancy; it represents less than 0.5% of all intracranial tumors. GSM usually affects often male in their fifth to sixth decade of life with supratentorial location especially in temporal lobes. The management of GS is extrapolated from glioblastoma with maximal gross total resection, and adjuvant radiotherapy with/without temozolomide. The prognosis is poor with median survival ranged from 06 to 14.8 months. The optimal treatment of GSM is unclear because of the lack of prospective studies. We report 04 cases (three cases of primary GSM and one case of secondary GSM) treated in our department of radiotherapy. Unfortunately, this publication confirmed the poor prognosis and the aggressive behavior of GSM tumors.